NCT04074343View on ClinicalTrials.gov

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

July 14, 2021

Study Completion Date

July 21, 2022

Conditions
Gastric AdenocarcinomaGastroEsophageal Cancer
Interventions
DRUG

TAS-102

Given PO

DRUG

Irinotecan

Given IV

Trial Locations (2)

92868

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

95817

UC Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

lead

University of California, Irvine

OTHER

NCT04074343 - TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | Biotech Hunter | Biotech Hunter